A panel of synthetic selective estrogen receptor modulators (SERMs), including tamoxifen and raloxifene, was prepared and used to treat ER-related diseases, including breast cancer and osteoporosis [212,213,215]. This evidence concerns the gene ESR1 and breast carcinoma.